[logo] HealthTree Foundation
search more_vert
close
person Sign In / Create Account
arrow_back

Go back to trials list

Phase 1, Open-label, Dose-escalation Trial with CD38-SADA:177 Lu-DOTA Drug Complex in Subjects with Relapsed or Refractory Non-Hodgkin Lymphoma


Description

Patients with non-Hodgkin Lymphoma will be treated with CD38-SADA:177Lu-DOTA complex (The IMP is a two-step radioimmunotherapy, delivered as two separate products CD38-SADA and 177Lu-DOTA) to establish optimal and safe therapeutic doses and dosing schedule of CD38-SADA, and 177Lu-DOTA.

Trial Eligibility

Inclusion Criteria: * Target population must have relapsed, progressive or refractory non-hodgkin lymphoma and be ineligible for or have exhausted standard therapeutic options that may prolong survival * The subject must have fluoro-deoxyglucose (FDG)-avid lymphoma with measurable disease * CD38 positive tumor at most recent biopsy (new or archival) documented at central laboratory * Subject must have an Eastern Cooperative Oncology Group (ECOG) performance status score of 0, 1, or 2 * Each subject must sign an ICF indicating that he or she understands the purpose of, and procedures required for the trial and is willing to participate in the trial. Exclusion Criteria: * Primary central nervous system lymphoma or known central nervous system involvement with lymphoma * Systemic chemotherapy, radiotherapy, immunotherapy, or major surgery administered within 3 weeks (for nitrosoureas within 6 weeks) prior to the first dose of CD38-SADA * Radioimmunotherapy within 100 days prior to the first dose of CD38-SADA * Autologous stem cell transplantation within 42 days prior to the first dose of CD38-SADA * Treatment with approved CAR-T within 100 days prior to the first dose of CD38-SADA * \>40% lymphoma bone marrow involvement

Study Info

Organization

Y-mAbs Therapeutics


Primary Outcome

Tumor imaging and occurrence of dose limiting toxicities (DLT) during the DLT evaluation period (Part A)


Outcome Timeframe 4 weeks

NCTID NCT05994157

Phases PHASE1

Primary Purpose TREATMENT

Start Date 2024-12

Completion Date 2027-01

Enrollment Target 30

Interventions

DRUG CD38-SADA:177Lu-DOTA Complex

Locations Recruiting

HonorHealth

United States, Arizona, Scottsdale


City of Hope

United States, California, Duarte


Corewell Health-BAMF Health

United States, Michigan, Grand Rapids


Memorial Sloan Kettering Cancer Center

United States, New York, New York


Stony Brook Cancer Center

United States, New York, Stony Brook


Interested in joining this trial?

Our dedicated patient navigators are here to guide you through the validation and enrollment process with ease.

newsletter icon

Get the latest thought leadership on your Lymphoma delivered straight to your inbox

Subscribe to the weekly newsletter for news, stories, clinical trial updates, and helpful resources and events with cancer experts.